Trial intelligence / Profile preview

Olaparib maintenance versus placebo in non-small cell lung cancer

2012-003383-51Phase 2Completed

Sponsor
Velindre University NHS Trust
Start
Jun 2013
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Olaparib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Jun 2013; status: completed.

02

Drugs

olaparib
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on 2012-003383-51.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-003383-51.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call